Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01946789
Title A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Altor Bioscience Corporation
Indications

head and neck squamous cell carcinoma

lung non-small cell carcinoma

melanoma

renal cell carcinoma

Therapies

ALT-803

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Minnesota Minneapolis Minnesota 55455 United States Details
Dartmouth Hitchcock Medical Center Lebanon New Hampshire 03756 United States Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08901 United States Details
Cleveland Clinic Foundation Cleveland Ohio 44195 United States Details
University of Washington, Seattle Cancer Care Alliance Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field